Abstract 15117: S100A12 Protein is a Marker to Predict Cardiovascular Events in Patients with Chronic Coronary Artery Diseases
Purpose: S100A12, a calgranulin family protein released from activated macrophages, is involved in inflammatory cardiovascular diseases. S100A12 binds to receptor for advanced glycation-end products (RAGE), leading to upregulation of nuclear factor kB. We hypothesized that plasma level of S100A protein can be a marker to predict prognosis of patients with chronic coronary artery disease (CAD). The purpose of this study is to clarify the clinical significance of S100A12 in patients with stable CAD.
Subjects and Methods: We studied 508 patients with stable CAD (mean age 63.8±9.6 years, male/female=419/89). All patients had received percutaneous coronary intervention (PCI) and revascularization was accomplished. Major adverse cardiovascular events (MACE) were defined as occurrence of congestive heart failure, coronary revascularization, acute myocardial infarction, stroke, and sudden cardiac death.
Results: Mean follow-up period was 690±298 days. MACE occurred in 55 patients (10.8%). Plasma levels of S100A12 showed significant positive correlation between white blood cell, platelet and high sensitive C-reactive protein (hsCRP) levels. We divided patients into two groups based on the median level of S100A12 (0.742 ng/mL). Kaplan-Meier curve analysis revealed that the high-S100A group showed significantly higher MACE rate than the low-S100A group (p=0.014). Univariate Cox analysis showed that left ventricular ejection fraction (LVEF), hsCRP, chronic kidney disease (CKD) and S100A protein are significant factors associated with MACE. Cox proportional hazard model including age, sex, LVEF, hsCRP, CKD and S100A12 showed that LVEF (hazard ratio :0.96, p=0.001) and S100A12 (hazard ratio:1.98, p=0.02) are independent factors to predict MACE.
Conclusions: Plasma S100A12, a marker of macrophage activation could be a novel biomarker for predicting cardiovascular events in patients with stable CAD.
- © 2011 by American Heart Association, Inc.